Bilateral administration of autologous CD133+ cells in ambulatory patients with refractory critical limb ischemia: Lessons learned from a pilot randomized, double-blind, placebo-controlled trial

Cytotherapy

Volumn 16, Issue 12, 2014, Pages 1720-1732

  Raval, Amish N ^a   Schmuck, Eric G ^a   Tefera, Girma ^a   Leitzke, Cathlyn ^a   Ark, Cassondra Vander ^a   Hei, Derek ^b   Centanni, John M ^a   de Silva, Ranil ^c   Koch, Jill ^a   Chappell, Richard G ^a   Hematti, Peiman ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c ROYAL BROMPTON AND HAREFIELD NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Angiogenesis; Critical limb ischemia; Peripheral artery disease; Stem cell

Indexed keywords

CD133 ANTIGEN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; GLYCOPROTEIN; LEUKOCYTE ANTIGEN; PEPTIDE;

AGED; AMBULATORY CARE; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CRITICAL LIMB ISCHEMIA; DOUBLE BLIND PROCEDURE; FEASIBILITY STUDY; FEMALE; FOLLOW UP; GENETIC ASSOCIATION; HUMAN; LEUKAPHERESIS; MALE; MULTICENTER STUDY; OVERALL SURVIVAL; PATIENT SAFETY; PILOT STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SENESCENCE; SURVIVAL RATE; THERAPY EFFECT; AUTOGRAFT; CLINICAL TRIAL; CONVALESCENCE; ISCHEMIA; LIMB; MIDDLE AGED; PATHOLOGY; PERIPHERAL ARTERIAL DISEASE; STEM CELL; STEM CELL TRANSPLANTATION; VASCULARIZATION;

AGED; ANTIGENS, CD; AUTOGRAFTS; DOUBLE-BLIND METHOD; EXTREMITIES; FEMALE; FOLLOW-UP STUDIES; GLYCOPROTEINS; HUMANS; ISCHEMIA; MALE; MIDDLE AGED; PEPTIDES; PERIPHERAL ARTERIAL DISEASE; RECOVERY OF FUNCTION; STEM CELL TRANSPLANTATION; STEM CELLS;

EID: 84911911315     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.1016/j.jcyt.2014.07.011     Document Type: Article

References (67)

1. Norgren L., Hiatt W.R., Dormandy J.A., Nehler M.R., Harris K.A., Fowkes F.G., et al. Inter-society consensus for the management of peripheral arterial disease (TASC II). Eur J Vasc Endovasc Surg 2007, 33(Suppl 1):S1-75.
2. Hirsch A.T., Haskal Z.J., Hertzer N.R., Bakal C.W., Creager M.A., Halperin J.L., et al. ACC/AHA 2005 practice guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): A collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA task force on practice guidelines (writing committee to develop guidelines for the management of patients with peripheral arterial disease): Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; Transatlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation 2006, 113:e463-654.
3. Becker F., Robert-Ebadi H., Ricco J.B., Setacci C., Cao P., de Donato G., et al. Chapter I: Definitions, epidemiology, clinical presentation and prognosis. Eur J Vasc Endovasc Surg 2011, 42(Suppl 2):S4-12.
4. de Vries S.O., Donaldson M.C., Hunink M.G. Contralateral symptoms after unilateral intervention for peripheral occlusive disease. JVasc Surg 1998, 27:414-421.
5. Rollins K.E., Jackson D., Coughlin P.A. Meta-analysis of contemporary short- and long-term mortality rates in patients diagnosed with critical leg ischaemia. Br J Surg 2013, 100:1002-1008.
6. Belch J., Hiatt W.R., Baumgartner I., Driver I.V., Nikol S., Norgren L., et al. Effect of fibroblast growth factor nv1fgf on amputation and death: A randomised placebo-controlled trial of gene therapy in critical limb ischaemia. Lancet 2011, 377:1929-1937.
7. Ma N., Ladilov Y., Moebius J.M., Ong L., Piechaczek C., David A., et al. Intramyocardial delivery of human cd133+ cells in a scid mouse cryoinjury model: Bone marrow vs. Cord blood-derived cells. Cardiovasc Res 2006, 71:158-169.
8. Gehling U.M., Ergun S., Schumacher U., Wagener C., Pantel K., Otte M., et al. In vitro differentiation of endothelial cells from ac133-positive progenitor cells. Blood 2000, 95:3106-3112.
9. Peichev M., Naiyer A.J., Pereira D., Zhu Z., Lane W.J., Williams M., et al. Expression of vegfr-2 and ac133 by circulating human cd34(+) cells identifies a population of functional endothelial precursors. Blood 2000, 95:952-958.
10. Friedrich E.B., Walenta K., Scharlau J., Nickenig G., Werner N. CD34-/CD133+/VEGFr-2+ endothelial progenitor cell subpopulation with potent vasoregenerative capacities. Circ Res 2006, 98:e20-25.
11. Tateishi-Yuyama E., Matsubara H., Murohara T., Ikeda U., Shintani S., Masaki H., et al. Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: A pilot study and a randomised controlled trial. Lancet 2002, 360:427-435.
12. Esato K., Hamano K., Li T.S., Furutani A., Seyama A., Takenaka H., et al. Neovascularization induced by autologous bone marrow cell implantation in peripheral arterial disease. Cell Transplant 2002, 11:747-752.
13. Huang P., Li S., Han M., Xiao Z., Yang R., Han Z.C. Autologous transplantation of granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cells improves critical limb ischemia in diabetes. Diabetes Care 2005, 28:2155-2160.
14. Miyamoto K., Nishigami K., Nagaya N., Akutsu K., Chiku M., Kamei M., et al. Unblinded pilot study of autologous transplantation of bone marrow mononuclear cells in patients with thromboangiitis obliterans. Circulation 2006, 114:2679-2684.
15. Durdu S., Akar A.R., Arat M., Sancak T., Eren N.T., Ozyurda U. Autologous bone-marrow mononuclear cell implantation for patients with rutherford grade ii-iii thromboangiitis obliterans. JVasc Surg 2006, 44:732-739.
16. Arai M., Misao Y., Nagai H., Kawasaki M., Nagashima K., Suzuki K., et al. Granulocyte colony-stimulating factor: A noninvasive regeneration therapy for treating atherosclerotic peripheral artery disease. Circ J 2006, 70:1093-1098.
17. Huang P.P., Yang X.F., Li S.Z., Wen J.C., Zhang Y., Han Z.C. Randomised comparison of g-csf-mobilized peripheral blood mononuclear cells versus bone marrow-mononuclear cells for the treatment of patients with lower limb arteriosclerosis obliterans. Thromb Haemost 2007, 98:1335-1342.
18. Kawamoto A., Katayama M., Handa N., Kinoshita M., Takano H., Horii M., et al. Intramuscular transplantation of g-csf-mobilized cd34(+) cells in patients with critical limb ischemia: A phase I/IIa, multicenter, single-blinded, dose-escalation clinical trial. Stem Cells 2009, 27:2857-2864.
19. Prochazka V., Gumulec J., Jaluvka F., Salounova D., Jonszta T., Czerny D., et al. Cell therapy, a new standard in management of chronic critical limb ischemia and foot ulcer. Cell Transplant 2010, 19:1413-1424.
20. Murphy M.P., Lawson J.H., Rapp B.M., Dalsing M.C., Klein J., Wilson M.G., et al. Autologous bone marrow mononuclear cell therapy is safe and promotes amputation-free survival in patients with critical limb ischemia. JVasc Surg 2011, 53:1565-1574.e1.
21. Lu D., Chen B., Liang Z., Deng W., Jiang Y., Li S., et al. Comparison of bone marrow mesenchymal stem cells with bone marrow-derived mononuclear cells for treatment of diabetic critical limb ischemia and foot ulcer: A double-blind, randomized, controlled trial. Diabetes Res Clin Pract 2011, 92:26-36.
22. Walter D.H., Krankenberg H., Balzer J.O., Kalka C., Baumgartner I., Schluter M., et al. Intraarterial administration of bone marrow mononuclear cells in patients with critical limb ischemia: A randomized-start, placebo-controlled pilot trial (provasa). Circ Cardiovasc Intervent 2011, 4:26-37.
23. Powell R.J., Marston W.A., Berceli S.A., Guzman R., Henry T.D., Longcore A.T., et al. Cellular therapy with ixmyelocel-t to treat critical limb ischemia: The randomized, double-blind, placebo-controlled restore-cli trial. Mol Ther 2012, 20:1280-1286.
24. Losordo D.W., Kibbe M.R., Mendelsohn F., Marston W., Driver V.R., Sharafuddin M., et al. Arandomized, controlled pilot study of autologous cd34+ cell therapy for critical limb ischemia. Circ Cardiovasc Intervent 2012, 5:821-830.
25. Benoit E., O'Donnell T.F., Iafrati M.D., Asher E., Bandyk D.F., Hallett J.W., et al. The role of amputation as an outcome measure in cellular therapy for critical limb ischemia: Implications for clinical trial design. JTranslat Med 2011, 9:165.
26. Teraa M., Sprengers R.W., van der Graaf Y., Peters C.E., Moll F.L., Verhaar M.C. Autologous bone marrow-derived cell therapy in patients with critical limb ischemia: A meta-analysis of randomized controlled clinical trials. Ann Surg 2013, 258:922-929.
27. Montgomery P.S., Gardner A.W. The clinical utility of a six-minute walk test in peripheral arterial occlusive disease patients. JAm Geriatr Soc 1998, 46:706-711.
28. Jia M., Souchelnytskyi N., Hellman U., O'Hare M., Jat P.S., Souchelnytskyi S. Proteome profiling of immortalization-to-senescence transition of human breast epithelial cells identified map2k3 as a senescence-promoting protein which is downregulated in human breast cancer. Proteomics Clin Appl 2010, 4:816-828.
29. Shibanuma M., Mochizuki E., Maniwa R., Mashimo J., Nishiya N., Imai S., et al. Induction of senescence-like phenotypes by forced expression of hic-5, which encodes a novel lim motif protein, in immortalized human fibroblasts. Mol Cell Biol 1997, 17:1224-1235.
30. West M.D., Shay J.W., Wright W.E., Linskens M.H. Altered expression of plasminogen activator and plasminogen activator inhibitor during cellular senescence. Exp Gerontol 1996, 31:175-193.
31. Dulic V., Drullinger L.F., Lees E., Reed S.I., Stein G.H. Altered regulation of g1 cyclins in senescent human diploid fibroblasts: Accumulation of inactive cyclin e-cdk2 and cyclin d1-cdk2 complexes. Proc Natl Acad Sci U S A 1993, 90:11034-11038.
32. Mikawa T., Maruyama T., Okamoto K., Nakagama H., Lleonart M.E., Tsusaka T., et al. Senescence-inducing stress promotes proteolysis of phosphoglycerate mutase via ubiquitin ligase mdm2. JCell Biol 2014, 204:729-745.
33. Handayaningsih A.E., Takahashi M., Fukuoka H., Iguchi G., Nishizawa H., Yamamoto M., et al. IGF-I enhances cellular senescence via the reactive oxygen species-p53 pathway. Biochem Biophys Res Commun 2012, 425:478-484.
34. Kim K.S., Seu Y.B., Baek S.H., Kim M.J., Kim K.J., Kim J.H., et al. Induction of cellular senescence by insulin-like growth factor binding protein-5 through a p53-dependent mechanism. Mol Biol Cell 2007, 18:4543-4552.
35. Johnson R.J., Xiao G., Shanmugaratnam J., Fine R.E. Calreticulin functions as a molecular chaperone for the beta-amyloid precursor protein. Neurobiol Aging 2001, 22:387-395.
36. Sheydina A., Volkova M., Jiang L., Juhasz O., Zhang J., Tae H.J., et al. Linkage of cardiac gene expression profiles and ETS2 with lifespan variability in rats. Aging Cell 2012, 11:350-359.
37. Chen Y., Ma X., Zhang M., Wang X., Wang C., Wang H., et al. Gadd45a regulates hematopoietic stem cell stress responses in mice. Blood 2014, 123:851-862.
38. Jackson J.G., Pereira-Smith O.M. P53 is preferentially recruited to the promoters of growth arrest genes p21 and gadd45 during replicative senescence of normal human fibroblasts. Cancer Res 2006, 66:8356-8360.
39. Lal A., Gorospe M. Egad, more forms of gene regulation: The gadd45a story. Cell Cycle 2006, 5:1422-1425.
40. Gualandi F., Morelli C., Pavan J.V., Rimessi P., Sensi A., Bonfatti A., et al. Induction of senescence and control of tumorigenicity in bk virus transformed mouse cells by human chromosome 6. Genes Chromosomes Cancer 1994, 10:77-84.
41. De Benedictis G., Carotenuto L., Carrieri G., De Luca M., Falcone E., Rose G., et al. Gene/longevity association studies at four autosomal loci (ren, tho, parp, sod2). Eur J Hum Genet 1998, 6:534-541.
42. Asahara T., Murohara T., Sullivan A., Silver M., van der Zee R., Li T., et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997, 275:964-967.
43. Bussolino F., Wang J.M., Defilippi P., Turrini F., Sanavio F., Edgell C.J., et al. Granulocyte- and granulocyte-macrophage-colony stimulating factors induce human endothelial cells to migrate and proliferate. Nature 1989, 337:471-473.
44. Poole J., Mavromatis K., Binongo J.N., Khan A., Li Q., Khayata M., et al. Effect of progenitor cell mobilization with granulocyte-macrophage colony-stimulating factor in patients with peripheral artery disease: A randomized clinical trial. JAMA 2013, 310:2631-2639.
45. Ringelstein E.B., Thijs V., Norrving B., Chamorro A., Aichner F., Grond M., et al. Granulocyte colony-stimulating factor in patients with acute ischemic stroke: Results of the ax200 for ischemic stroke trial. Stroke 2013, 44:2681-2687.
46. Zohlnhofer D., Ott I., Mehilli J., Schomig K., Michalk F., Ibrahim T., et al. Stem cell mobilization by granulocyte colony-stimulating factor in patients with acute myocardial infarction: A randomized controlled trial. JAMA 2006, 295:1003-1010.
47. Ripa R.S., Jorgensen E., Wang Y., Thune J.J., Nilsson J.C., Sondergaard L., et al. Stem cell mobilization induced by subcutaneous granulocyte-colony stimulating factor to improve cardiac regeneration after acute st-elevation myocardial infarction: Result of the double-blind, randomized, placebo-controlled stem cells in myocardial infarction (stemmi) trial. Circulation 2006, 113:1983-1992.
48. Engelmann M.G., Theiss H.D., Hennig-Theiss C., Huber A., Wintersperger B.J., Werle-Ruedinger A.E., et al. Autologous bone marrow stem cell mobilization induced by granulocyte colony-stimulating factor after subacute st-segment elevation myocardial infarction undergoing late revascularization: Final results from the G-CSF-STEMI (granulocyte colony-stimulating factor ST-segment elevation myocardial infarction) trial. JAm Coll Cardiol 2006, 48:1712-1721.
49. Zafarghandi M.R., Ravari H., Aghdami N., Namiri M., Moazzami K., Taghiabadi E., et al. Safety and efficacy of granulocyte-colony-stimulating factor administration following autologous intramuscular implantation of bone marrow mononuclear cells: A randomized controlled trial in patients with advanced lower limb ischemia. Cytotherapy 2010, 12:783-791.
50. Ozturk A., Kucukardali Y., Tangi F., Erikci A., Uzun G., Bashekim C., et al. Therapeutical potential of autologous peripheral blood mononuclear cell transplantation in patients with type 2 diabetic critical limb ischemia. JDiabetes Complications 2012, 26:29-33.
51. Maksimov A.V., Kiiasov A.P., Plotnikov M.V., Maianskaia S.D., Shamsutdinova, Gazizov I.M., et al. [outcomes of using autologous peripheral-blood stem cells in patients with chronic lower arterial insufficiency]. Angiol Sosud Khir 2011, 17:11-15.
52. Dubsky M., Jirkovska A., Bem R., Pagacova L., Fejfarova V., Varga M., et al. [treatment of critical limb ischemia and diabetic foot disease by the use of autologous stem cells]. Vnitr Lek 2011, 57:451-455.
53. Mohammadzadeh L., Samedanifard S.H., Keshavarzi A., Alimoghaddam K., Larijani B., Ghavamzadeh A., et al. Therapeutic outcomes of transplanting autologous granulocyte colony-stimulating factor-mobilised peripheral mononuclear cells in diabetic patients with critical limb ischaemia. Exp Clin Endocrinol Diabetes 2013, 121:48-53.
54. Burt R.K., Testori A., Oyama Y., Rodriguez H.E., Yaung K., Villa M., et al. Autologous peripheral blood cd133+ cell implantation for limb salvage in patients with critical limb ischemia. Bone Marrow Transplant 2010, 45:111-116.
55. Canizo M.C., Lozano F., Gonzalez-Porras J.R., Barros M., Lopez-Holgado N., Briz E., et al. Peripheral endothelial progenitor cells (CD133+) for therapeutic vasculogenesis in a patient with critical limb ischemia. One year follow-up. Cytotherapy 2007, 9:99-102.
56. Jonsson T.B., Larzon T., Arfvidsson B., Tidefelt U., Axelsson C.G., Jurstrand M., et al. Adverse events during treatment of critical limb ischemia with autologous peripheral blood mononuclear cell implant. Int Angiol 2012, 31:77-84.
57. Pignon B., Sevestre M.A., Chatelain D., Albertini J.N., Sevestre H. Histological changes after implantation of autologous bone marrow mononuclear cells for chronic critical limb ischemia. Bone Marrow Transplant 2007, 39:647-648.
58. Duong Van Huyen J.P., Smadja D.M., Bruneval P., Gaussem P., Dal-Cortivo L., Julia P., et al. Bone marrow-derived mononuclear cell therapy induces distal angiogenesis after local injection in critical leg ischemia. Mod Pathol 2008, 21:837-846.
59. Hill J.M., Zalos G., Halcox J.P., Schenke W.H., Waclawiw M.A., Quyyumi A.A., et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. NEngl J Med 2003, 348:593-600.
60. Vasa M., Fichtlscherer S., Aicher A., Adler K., Urbich C., Martin H., et al. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res 2001, 89:E1-E7.
61. Chen Y.L., Chang C.L., Sun C.K., Wu C.J., Tsai T.H., Chung S.Y., et al. Impact of obesity control on circulating level of endothelial progenitor cells and angiogenesis in response to ischemic stimulation. JTranslat Med 2012, 10:86.
62. Tepper O.M., Galiano R.D., Capla J.M., Kalka C., Gagne P.J., Jacobowitz G.R., et al. Human endothelial progenitor cells from type II diabetics exhibit impaired proliferation, adhesion, and incorporation into vascular structures. Circulation 2002, 106:2781-2786.
63. Rauscher F.M., Goldschmidt-Clermont P.J., Davis B.H., Wang T., Gregg D., Ramaswami P., et al. Aging, progenitor cell exhaustion, and atherosclerosis. Circulation 2003, 108:457-463.
64. Teraa M., Sprengers R.W., Westerweel P.E., Gremmels H., Goumans M.J., Teerlink T., et al. Bone marrow alterations and lower endothelial progenitor cell numbers in critical limb ischemia patients. PLoS One 2013, 8:e55592.
65. Subherwal S., Anstrom K.J., Jones W.S., Felker M.G., Misra S., Conte M.S., et al. Use of alternative methodologies for evaluation of composite end points in trials of therapies for critical limb ischemia. Am Heart J 2012, 164:277-284.
66. Sherman W., Mazouz C., Deans R., Patel A.N. Commercialization of trials for peripheral artery disease. Cytotherapy 2011, 13:1157-1161.
67. Losordo D.W., Henry T.D., Davidson C., Sup Lee J., Costa M.A., Bass T., et al. Intramyocardial, autologous cd34+ cell therapy for refractory angina. Circ Res 2011, 109:428-436.